News

Affimed N.V. Reports Strong Q3 2024 Financial Outcomes

Affimed N.V. Reports Strong Q3 2024 Financial Outcomes

Affimed N.V. Reports Strong Q3 2024 Financial Outcomes

Affimed N.V. (Nasdaq: AFMD), a leader in immuno-oncology, recently shared its financial results and outlined significant developments in its clinical pipeline for the recent quarter. The company, recognized for its commitment to leveraging the innate immune system in cancer therapy, reported that its current cash reserves are projected to support operations into late 2025.

Clinical Pipeline Updates

One impressive highlight for Affimed includes the completion of patient enrollment in the AFM24-102 trial, which combines their novel therapy AFM24 with atezolizumab for the treatment of non-small cell lung cancer (NSCLC) with EGFR wild-type. Safety and early clinical efficacy results from this cohort will be revealed in a future conference call.

Noteworthy Clinical Combinations

In addition, the company is gearing up to present updated clinical data surrounding Acimtamig (AFM13) used alongside AlloNK® at the upcoming ASH 2024. Four distinct cohorts are being highlighted during this session, aiming to showcase the potential of this collaboration in treating patients with hard-to-treat cancers.

AFM28 Monotherapy Study

Affimed also continues to provide updates from its AFM28 phase 1 dose-escalation study for relapsed or refractory acute myeloid leukemia (AML). Updated clinical data is expected to be shared during an oral presentation at ASH 2024, shedding light on the safety and effectiveness of AFM28.

Financial Highlights

As of September 30, 2024, Affimed's total cash, cash equivalents, and short-term investments were reported at €24.1 million. This figure indicates a significant drop from the previous year's reported numbers but reflects the company's strategic financial management amid reduced expenses in research and development. The net cash utilized in operations for Q3 2024 amounted to €11.1 million, showcasing a decrease from €18.3 million in the same quarter the previous year.

Revenue Insights

The total revenue for Affimed in Q3 2024 was €0.2 million, down from €2.0 million in the same period last year, primarily due to differences in collaborative agreements. Revenue in the current quarter derives mainly from licensing arrangements, contrasting with last year’s higher collaborations in research.

Continued Investment in R&D

Research and Development expenses for the same quarter were pegged at €10.1 million, significantly lower than in 2023, reflecting Affimed's commitment to refining its clinical focus while balancing cost-effective operations. While general and administrative expenses also declined to €4.3 million, this reflects the company’s focus on efficiency amidst ongoing operational changes.

Looking Ahead at Future Milestones

Going forward, Affimed has significant milestones to anticipate, including updates on efficacy from the LuminICE-203 study and data presentation from the AFM24-102 trial in 2025. With these upcoming events, Affimed aims to solidify its position within the competitive landscape of immuno-oncology.

About Affimed N.V.

Affimed N.V. is firmly rooted in the advancement of immunotherapy, utilizing its proprietary ROCK® platform to design innate cell engagers (ICE®). These innovative therapies enable targeted treatments for various cancers, indicating a promising path forward for patients battling challenging diagnoses. Headquartered in Mannheim, Germany, the company is committed to turning the tide on cancer through extensive research and robust clinical partnerships.

Frequently Asked Questions

What are the main highlights from Affimed's Q3 2024 report?

Affimed reported a cash position of €24.1 million, a reduction in R&D expenses, and updates on their clinical pipeline.

When will data on AFM24 be available?

The objective response rate and safety data from the AFM24 combination therapy will be presented in a future conference call.

What financial results did Affimed report for Q3 2024?

The company reported total revenue of €0.2 million and a net cash used in operations of €11.1 million.

How has Affimed's revenue changed compared to last year?

Revenue decreased from €2.0 million in Q3 2023 to €0.2 million in the recent quarter.

What is Affimed's strategic focus moving forward?

The company aims to optimize its clinical priorities, demonstrate impactful collaborations, and drive efficiencies in its R&D efforts.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BOC Group's Challenger Role Eye-Opener in Gartner Quadrant

Updated Category News Views 0

Cracking the Challenger Code: BOC Group's Debut Ever heard of BOC Group? If you haven’t, it’s time to pay attention. This Dublin-based outfit just muscled its way into the Challenger Quadrant of the 2026 Gartner Magic Quadrant for Digital Twin of an Organization Platforms. Not bad for its first trip to the dance. When a company crashes the scene like this, eyebrows...

Continue Reading
Rethinking Roof Lifespans for Harsh Michigan Winters

Updated Category News Views 0

Unraveling the Michigan Roof Lifespan Myth When most folks think about the lifespan of their roof, especially in a place like Michigan, they tend to believe those thirty-year warranties plastered all over asphalt shingles. But that's the fairy tale version, folks. Tom Meadows, a roofing expert from Ann Arbor, wants residents to wake up to a chilling reality—Michigan's...

Continue Reading
Rice University's Explosive Growth Story: 2026 Outlook

Updated Category News Views 2

Charting a Path to New Heights Who would've thought a small campus in Houston could make waves this big? Rice University, the underdog rising through the ranks, is kicking off a historic growth phase. With application numbers through the roof and a flood of new students on campus, it's time to peek behind the curtain and see what this means for the institution that's...

Continue Reading
How Shelton's Property Taxes Influence Housing Costs

Updated Category News Views 2

Thinking about snapping up a home in Shelton, Connecticut? Well, you might want to keep an eye on those property taxes first. Sure, mortgage rates and listing prices grab all the initial attention, but taxes—oh boy, they know how to creep up on ya. Matt Nuzie from RE/MAX lays it bare: property taxes can make or break the bank for homebuyers in Fairfield County. So,...

Continue Reading
BNI Sets Sights on Big Expansion Across Europe

Updated Category News Views 2

BNI Charges Forward: Europe Expansion Strategy This one's got me thinking about how networking giants like BNI are not sitting back comfortably, they're on the move. BNI is going all-in on Europe, making serious waves by locking down new franchise territories in France, Italy, and the UK. It's no small feat—they already have a footprint there with over 35,000 members...

Continue Reading
ONTO Faces Fiduciary Duty Investigation Alert

Updated Category News Views 2

Possible Fiduciary Abuses at Onto Innovation Imagine you’re cruising down the investment highway when, bam, an alert like this pops up in your rearview mirror. It’s time to hit the brakes and figure out what Levi & Korsinsky is up to with this investigation into Onto Innovation Inc. (NYSE: ONTO). They're sniffing around possible breaches of fiduciary duties by some of...

Continue Reading
Mech-Mind Robotics Debuts on HKEX: A Game Changer

Updated Category News Views 3

Mech-Mind Robotics has been strutting its stuff on the Hong Kong Stock Exchange, stepping right onto the stage with a market cap that tips the scales at a hefty HK$12.71 billion. Not every day you see a fresh face in the AI space commanding that kind of attention, but when you dig into the details, well, maybe it isn't all that surprising after all. A Strategic Player in...

Continue Reading
Claroty Earns Top Marks in OT Security Evaluation

Updated Category News Views 4

A Closer Look at Claroty's Forrester Acclaim The waves of cybersecurity analysis have peeled back again, revealing a shining star—Claroty. The latest third-party evaluations seem to show that this beast of a company isn't just cruising; it's tearing up the operational technology security landscape. Named as both a 'Leader' and a 'Customer Favorite' in The Forrester...

Continue Reading
Quandri Joins Applied Systems Certification for AI Edge

Updated Category News Views 1

Quandri Steps Into the Limelight with Vendor Certification Alright, so you’ve got Quandri, an up-and-coming player on the insurance tech scene, making some hefty strides by snatching a coveted spot in Applied Systems' brand new Vendor Certification Program. Yeah, it sounds like another day at the software club, but what this really means is less runaround and more...

Continue Reading
Ignyte Insurance Acquires InsureMyTrip to Expand Portfolio

Updated Category News Views 1

Key Acquisition: Strengthening Global Presence Ignyte Insurance just added a major player to its roster with the acquisition of InsureMyTrip. No two ways about it, this move is about expanding their footprint in the booming travel and medical insurance sector. Now, if you've ever thought travel insurance was just fine print nobody reads, think again. This industry’s got...

Continue Reading

Top 5 Most Recently Viewed Articles

ONEOK Completes Strategic Medallion Midstream Acquisition

Updated Category News Views 130

ONEOK Completes Strategic Medallion Midstream Acquisition The journey towards enhanced energy infrastructure continues as ONEOK, Inc. (NYSE: OKE) has successfully finalized its acquisition of Medallion Midstream from Global Infrastructure Partners. With this monumental transaction valued at approximately $2.6 billion, ONEOK adds a pivotal asset to its growing portfolio....

Continue Reading
Stolen Sculptures by Sir Daniel Winn Worth Millions

Updated Category News Views 209

High-Profile Theft: Two Major Sculptures Stolen Renowned Artist and Airport Art Commissioner Targeted in Sophisticated Heist This week, an incredible theft took place, marking a stunning incident for the art community. Two monumental sculptures by well-known artist Sir Daniel Winn, valued together at more than $2.15 million, were stolen from a secure facility. Local...

Continue Reading
UniFirst Corporation: Analyst Insights and Earnings Outlook

Updated Category News Views 107

Overview of UniFirst Corporation UniFirst Corporation (NYSE: UNF) is poised to release its earnings results for the first quarter soon. As analysts prepare for this significant milestone, there are noteworthy changes in forecasts that are shaping expectations for the company. The release of earnings will occur before the market opens, and many are eager to see how well...

Continue Reading
Alstom Invests Over €150 Million to Boost Production Capacity

Updated Category News Views 346

Alstom's Major Investment to Enhance Production in France Alstom is making significant strides toward strengthening its production capabilities in France with an investment plan exceeding €150 million. This initiative aims to address the upsurge in demand for rail transportation, especially for very high-speed trains. The automotive and rail industries have seen vast...

Continue Reading
International Money Express Secures $425 Million Credit Facility

Updated Category News Views 71

International Money Express, Inc. Secures $425 Million Credit Facility International Money Express, Inc. (NASDAQ: IMXI), a prominent omni-channel money remittance company, has successfully refinanced its existing secured debt by establishing a new revolving credit facility worth $425 million. This new credit agreement allows for loans in U.S. Dollars, Euros, and Pound...

Continue Reading